Oncotarget, a peer review that has open access to all medical journals that cover the research on all parts of oncology. The editors-in-chief, are Mikhail Blagosklonny, is a professor at Roswell Park Cancer Institute in New York in oncology, and Andrei V. Gudkov, a professor of biochemistry at Case Western University in Cleveland, Ohio whose field is in cell stress biology. Oncotarget was first published in 2010 by Impact Journals.
The growing popularity of Oncotarget is due to multiple peer-reviews that are constructive, insightful and in a small time period for punctuality. This punctuality helps the authors of future articles to increase their research impact.
Four members of Oncotarget -Oncoscience-Gerotarget, Bert Vogelstein, Michael N Hall, Stephen J. Elledge and Alexander Varshavsky, have been awarded the largest prize ever by winning the Breakthrough Prize.
Oncotarget is a term that covers all areas of the cancer and aging process, cellular functions, and molecules that are known to be common in neurodegeneration, atherosclerosis, lymphocytes, and the many cancer cells, microbes, and neurons that are associated with the aging process and cancer growth. Learn more about Oncotarget at Bioxbio.com.
Their ultimate mission is to make the results of scientific study and research available in a rapid and timely manner and to make it widely available to all researchers in their chosen field. They wish to make it possible for any exceptional findings and discoveries to be shared with like-minded scientists quickly. With their insightful review’s, they want to maximize the research’s impact. Also, to link the different fields of biomedical study and eliminate the lines between specialties as well as fostering the applications of the basic and clinical science with which to fight disease. In the end, their ultimate goal is to help the scientists and researchers who contribute their findings to Oncotarget to fight to make life without disease possible. Oncotarget is also available on Dove Press.
They are now launching new sections going beyond oncology. They do publish findings in the fields of endocrinology, pathology, physiology, immunology, and all age-related diseases. In the future, they will be publishing researcher’s papers on Stem Cell and Neuroscience discoveries.
Oncotarget also focuses on management programs, and the perspective of patients at to the quality of life, as well as new therapeutic agents.